BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Gastrointestinal Health Product Already Approved by Health Canada-2014 Launch Planned
March 04, 2014 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - March 4, 2014) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive...
BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years
February 13, 2014 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Feb. 13, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that it has again been named as one of the TSX Venture Top 50 companies.
...
BioSyent Announces Appointment of New Director
January 16, 2014 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Jan. 16, 2014) - The Board of Directors of BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce the appointment of Stephen Wilton to the...
BioSyent to Present at the LD Micro VI Investor Conference
December 02, 2013 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Dec. 2, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the LD...
BioSyent Releases Q3 and Nine Month Results-Nine Month Sales Increase 53% and Profit Before Tax Up 77%
November 21, 2013 06:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Nov. 21, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months (Q3) and nine months...
BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Women's Health Product Already Approved by Health Canada-2014 Launch Planned
October 01, 2013 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Oct. 1, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive...
BioSyent Releases Q2 and Six Month Results: Six Month Sales Increase 57% and Profit Before Tax Up 68%
August 22, 2013 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Aug. 22, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its second quarter (Q2) and first half (H1) 2013 financial...
BioSyent Pharma Launches New FeraMAX(R) Powder-Water Soluble Polysaccharide-Iron Complex Iron Supplement
June 06, 2013 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - June 6, 2013) - BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of...
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 Year Revenue Growth Rate of 355%
June 04, 2013 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - June 4, 2013) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that PROFIT Magazine has ranked BioSyent as one of Canada's Fastest-Growing...
BioSyent Pharma Submits Two New Drugs to Health Canada for Marketing Approval
May 23, 2013 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - May 23, 2013) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that its subsidiary, BioSyent Pharma Inc., has submitted two new drug products...